Evidence map›Paper›PMID 40764067›Full record

ArticleBMJ open2025

Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science study protocol.

Beth Bourdeau, Greg Rebchook, Starley B Shade, Jesse O'Shea, Kate Buchacz, Orlando Harris, Mallory O Johnson, Michelle Palomares, Alicia T Bolton, Jonathan Van Nuys and 2 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06488846 (Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06488846 enrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home

TypeobservationalSponsorUniversity of California, San FranciscoRan2026 to 2027Enrolled1,000ConditionsHIV InfectionsArmsINVITE-Home, Clinic-Administered LAI-ART, Oral ART
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Beth BourdeauMedicine, University of California San Francisco, San Francisco, California, USA Beth.Bourdeau@ucsf.edu.ORCID http://orcid.org/0000-0001-7537-6350
Greg RebchookMedicine, University of California San Francisco, San Francisco, California, USA.
Starley B ShadeMedicine, University of California San Francisco, San Francisco, California, USA.
Jesse O'SheaCDC, Atlanta, Georgia, USA.
Kate BuchaczCDC, Atlanta, Georgia, USA.
Orlando HarrisDepartment of Community Health Systems, University of California San Francisco, San Francisco, California, USA.
Mallory O JohnsonMedicine, University of California San Francisco, San Francisco, California, USA.
Michelle PalomaresMedicine, University of California San Francisco, San Francisco, California, USA.
Alicia T BoltonMedicine, University of California San Francisco, San Francisco, California, USA.
Jonathan Van NuysMedicine, University of California San Francisco, San Francisco, California, USA.
Erin MooreMedicine, University of California San Francisco, San Francisco, California, USA.
Parya SaberiMedicine, University of California San Francisco, San Francisco, California, USA.ORCID http://orcid.org/0000-0002-3793-5112

Funding

NCHHSTP CDC HHS U01 PS005259
6 · The paper itself

Abstract

introductionThere is high interest in long-acting injectable antiretroviral therapy (LAI-ART) among people with HIV (PWH), with many conveniences for uptake and persistence. However, both patients and clinicians have expressed important barriers to effective implementation, including concerns about frequent clinic visits and strain on clinic resources. Administration of LAI-ART by a trained layperson injector (such as family, friend or partner of the patient) can help mitigate some of these patient-identified and clinician-identified barriers. Alternative LAI-ART delivery methods have the potential to increase the PWH and layperson injector's confidence, empowerment, convenience, privacy and self-management skills and ultimately facilitate LAI-ART uptake and persistence. METHODS AND ANALYSIS: INVITE-Home (innovative administration of long-acting injectables for HIV treatment enhancement at home) will support the expansion of LAI-ART in non-clinical settings by developing, implementing and evaluating a comprehensive, theory-informed training to support the administration of LAI-ART by a trained layperson injector. First, INVITE-Home will design and develop an innovative, theory-based layperson injector training to improve acceptability and uptake of LAI-ART in home-based settings, grounded in qualitative evaluation of training barriers and needs of PWH, layperson injectors and clinicians to develop the training. In Aim 2, INVITE-Home will enhance understanding of home-based LAI-ART using the training, by examining implementation and effectiveness of home-based LAI-ART injections. ETHICS AND DISSEMINATION: This study and its protocols have been approved by the University of California, San Francisco (UCSF) Institutional Review Board and the scientific staff of HIV Research Branch, Division of HIV Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, at the Centers for Disease Control and Prevention. Study staff will disseminate findings locally (eg, to partnering clinics, via the UCSF Center for AIDS Prevention Studies' Community Engagement Core), statewide (eg, the California Department of Public Health's Office of AIDS) and nationally at conferences related to HIV. TRIAL REGISTRATION NUMBER: NCT06488846.

Indexed as

Anti-HIV AgentsHIV InfectionsHome Care ServicesDelayed-Action PreparationsHumansImplementation ScienceInjectionsMedication AdherenceAnti-HIV AgentsDelayed-Action PreparationsAdministrationFeasibility StudiesHealth ServicesHIV & AIDSImplementation Science

Identifiers

PMID40764067
PMCPMC12336619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.